New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Lexaria Bioscience Corp. (LEXX) vs Lisata Therapeutics, Inc. (LSTA)

Lexaria Bioscience Corp. and Lisata Therapeutics, Inc. are both Biotechnology companies. Lexaria Bioscience Corp. and Lisata Therapeutics, Inc. are of similar size ($9.8M and $9.5M). Lisata Therapeutics, Inc. grew revenue faster over the last twelve months: 57.2% against 52.0%. Lisata Therapeutics, Inc. has the higher net margin (−274.9% vs −1,686.1%) and the higher return on invested capital (0.00% vs −662.6%). Across the 16 metrics below, Lisata Therapeutics, Inc. leads on 12 and Lexaria Bioscience Corp. on 4.

Valuation

Metric LEXX LSTA Biotechnology median
P/E n/m n/m 8.49
P/S 12.30 0.55 8.56
P/B 1.53 1.10 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 12.46 0.69
EV/Sales 5.63 (18.03) 8.00
Earnings yield (129.52%) (208.82%) (35.81%)
Free cash flow yield (112.89%) (258.67%) (25.41%)

Profitability

Metric LEXX LSTA Biotechnology median
Gross margin 99.62% 14.13% 70.18%
Operating margin (1,683.06%) (398.56%) 0.00%
Net margin (1,686.05%) (274.88%) 0.00%
Free cash flow margin (1,494.56%) (137.78%) 0.00%
Return on equity (162.60%) (138.59%) (51.58%)
Return on assets (134.20%) (5.12%) (45.91%)
Return on invested capital (662.56%) 0.00% 0.00%

Growth

Metric LEXX LSTA Biotechnology median
Revenue growth (TTM) 52.04% 57.16% 7.20%
EPS growth (last fiscal year) (40.43%) 20.42% 29.04%
Revenue growth, 5-year CAGR 17.53% — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric LEXX LSTA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.60 14.09 4.79
Net debt to EBITDA 0.17 0.88 1.01

Dividend

Metric LEXX LSTA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LEXX LSTA Biotechnology median
Market cap 9.46m 9.83m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack